Influenza vaccination among persons with work-related asthma

Trends and factors associated with influenza vaccination in subjects with asthma: analysis of the Korea National Health and Nutrition Examination Survey between 2010 and 2019

BACKGROUND

Despite the importance of influenza vaccination, its rates in subjects with asthma are suboptimal, especially in the young population.

METHODS

Among 72,843 adults aged ⩾18 years from the Korea National Health and Nutrition Examination Survey conducted between 2010 and 2019, 1643 with asthma were included. The yearly trends and factors associated with influenza vaccination were analyzed in subjects with asthma. In addition, stratified analyses were performed by age group (<65 versus ⩾65 years).

RESULTS

During the study period, the overall influenza vaccination rate among subjects with asthma fluctuated from 51.0% to 64.3%, with a consistently higher vaccination rate in elderly subjects than in young subjects. Among young subjects with asthma, factors positively associated with influenza vaccination were female sex [adjusted odds ratio (aOR) = 1.66, 95% confidence interval (CI) = 1.11-2.49], current asthma being treated (aOR = 1.69, 95% CI = 1.14-2.50), history of pulmonary tuberculosis (aOR = 2.01, 95% CI = 1.04-3.87), and dyslipidemia (aOR = 1.86, 95% CI = 1.05-3.30). However, unmarried subjects showed an inverse relationship (aOR = 0.50, 95% CI = 0.34-0.75). In elderly subjects, unmarried status (aOR = 0.52, 95% CI = 0.29-0.94), being underweight (aOR = 0.29, 95% CI = 0.09-0.97), and having a low income (aOR = 0.42, 95% CI = 0.18-0.97) were factors negatively associated with influenza vaccination.

CONCLUSION

In the last 10 years, influenza vaccination rates have still been insufficient in subjects with asthma, particularly in young subjects. Considering the factors that are influencing the vaccination rates of young subjects, public policies to increase influenza vaccination rates in subjects with asthma need to be established urgently.

Pneumococcal Vaccine in Adult Asthma Patients

Streptococcus pneumoniae is the most frequent source of community-acquired bacterial pneumonia in adults. Respiratory tract infections are the foremost reasons for asthma exacerbations. The World Health Organization and the Centers for Disease Control and Prevention consider asthma a clear indication for pneumococcal vaccination. The aim of this study was to determine the extent to which adult patients with asthma in Poland adhere to a schedule of recommended pneumococcal vaccinations. In addition, the study attempted to assess the source of the patient knowledge on vaccination and the plausible determents for vaccination. The study was conducted among patients at specialist outpatient clinics in the form of an anonymous survey that contained questions about asthma, vaccines, and the knowledge and motivations. A total of 214 patients (149 females and 65 males) of the mean age of 52 ± 17 years were interviewed. A staggering 93% of patients did not receive pneumococcal vaccination, and only 24% of patients were aware of the need for this vaccine. Age, gender, and education did not affect whether patients chose to receive the vaccine. The most often quoted reason for not receiving the vaccine was lack of information, followed by lack of faith in vaccine efficacy, and the fear of adverse effects. From the standpoint of health hazard stemming from prophylaxis avoidance, it appears paramount to educate asthmatic patients on the benefits of receiving pneumococcal vaccination.

Factors Affecting Influenza Vaccination Rate in Adults with Asthma

Asthma is considered one of the most common noncommunicable diseases worldwide, with an incidence of 5.4% in the Polish, adult population. Symptoms of the disease can be triggered or worsened by a variety of factors including viral infection such as influenza, affirming the necessity for prophylactic vaccination. However, there is concern among the general population of the possibility of anaphylactic response to vaccination, which can deter patients with allergic asthma for fear of triggering exacerbation of their condition. The objective of the study was to determine the extent to which patients with asthma adhere to a schedule of recommended vaccinations in Poland. Two hundred fourteen patients were recruited from specialist outpatient clinics in Warsaw to complete voluntarily an anonymous questionnaire created for the purpose of this study. Within the past year, 82% stated having at least one respiratory infection, and 72% of patients were aware of the recommendation for annual vaccination against the flu. Forty-three percent of patients reported receiving the flu vaccine at least once, and only 20% followed through with annual vaccination. The most common sources of information about the importance of annual flu vaccination were from their doctors (47%) and the media (26%). Relatively few asthmatic patients in Warsaw get annual flu vaccinations despite the recommendations. These results were mainly sourced due to uncorrected fears and a lack of information about the importance of prophylaxis in asthma. It is essential to create effective strategies to inform patients with asthma of the importance of annual vaccinations.

Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force

To address uncertainties in the prevention and management of influenza in people with asthma, we performed a scoping review of the published literature on influenza burden; current vaccine recommendations; vaccination coverage; immunogenicity, efficacy, effectiveness, and safety of influenza vaccines; and the benefits of antiviral drugs in people with asthma. We found significant variation in the reported rates of influenza detection in individuals with acute asthma exacerbations making it unclear to what degree influenza causes exacerbations of underlying asthma. The strongest evidence of an association was seen in studies of children. Countries in the European Union currently recommend influenza vaccination of adults with asthma; however, coverage varied between regions. Coverage was lower among children with asthma. Limited data suggest that good seroprotection and seroconversion can be achieved in both children and adults with asthma and that vaccination confers a degree of protection against influenza illness and asthma-related morbidity to children with asthma. There were insufficient data to determine efficacy in adults. Overall, influenza vaccines appeared to be safe for people with asthma. We identify knowledge gaps and make recommendations on future research needs in relation to influenza in patients with asthma.

Pneumococcal Vaccination Among Adults With Work-related Asthma

INTRODUCTION

Pneumococcal vaccination is recommended for all adults with asthma and a Healthy People 2020 goal aims to achieve 60% coverage among high-risk adults, including those with asthma. Adults with work-related asthma have more severe asthma symptoms than those with non-work-related asthma and are particularly vulnerable to pneumococcal pneumonia.

METHODS

To assess pneumococcal vaccination coverage by work-related asthma status among ever-employed adults aged 18-64 years with current asthma, data from the 2012-2013 Behavioral Risk Factor Surveillance System Asthma Call-back Survey for ever-employed adults (18-64 years) with current asthma from 29 states were examined in 2016. Adults with work-related asthma had ever been told by a physician their asthma was work-related. Pneumococcal vaccine recipients self-reported having ever received a pneumococcal vaccine. Multivariate logistic regression was used to calculate adjusted prevalence ratios and associated 95% CIs.

RESULTS

Among an estimated 12 million ever-employed adults with current asthma in 29 states, 42.0% received a pneumococcal vaccine. Adults with work-related asthma were more likely to have received a pneumococcal vaccine than adults with non-work-related asthma (53.7% versus 35.0%, respectively, prevalence ratio=1.24, 95% CI=1.06, 1.45). Among adults with work-related asthma, pneumococcal vaccine coverage was lowest among Hispanics (36.2%) and those without health insurance (38.5%).

CONCLUSIONS

Pneumococcal vaccination coverage among adults with work-related asthma and non-work-related asthma is below the Healthy People 2020 target level. Healthcare providers should verify pneumococcal vaccination status in their patients with asthma and offer the vaccine to those not vaccinated.